{
  "id": 19170578,
  "title": "STAT+: Gene therapy’s long-debated cancer risk materializes",
  "url": "https://urgent.news/2026/11/09/stat-gene-therapys-long-debated-cancer-risk-materializes",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-09T14:36:12.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/11/09/biotech-news-gene-therapy-long-debated-cancer-risk-materializes/"
  },
  "original_language": "en",
  "account": "The story of gene therapy's unexpected cancer risk has emerged, casting a shadow over the promising field of pediatric treatments. Vir Biotechnology's recent trials showcased the potential of monthly injections for hepatitis D virus reduction, with 44% of patients achieving undetectable levels compared to none receiving delayed treatment. This marked a successful primary goal in a Phase 3 study.\n\nHowever, not all news is positive in the realm of gene therapies. Zura Bio's experimental antibody tibulizumab did not improve the symptoms of hidradenitis suppurativa, a debilitating inflammatory skin condition, compared to a placebo in a mid-stage study. The lack of efficacy in this case serves as a reminder that scientific progress is not without its setbacks.\n\nRoivant Sciences, on the other hand, reported a different outcome with its recently approved drug Lisraya for dermatomyositis treatment. The drug generated $31 million in sales within five weeks of approval, demonstrating that some gene therapies can indeed find success in the market.\n\nAdditionally, Argentum Ventures acquired Unnatural Products, a medicinal chemistry company with expertise in protein-based drugs. This acquisition highlights the ongoing innovation and investment in the biotechnology sector.\n\nThe story takes a somber turn as two heart trials at the American Heart Association meeting failed to deliver the expected results, despite the promise of artificial intelligence in drug discovery. These setbacks serve as a reminder that the road to breakthrough therapies is fraught with challenges and uncertainties, even as AI technologies are hailed as the future of drug development.",
  "summary": "For years, gene therapy researchers debated whether the viruses they use to ferry replacement genes into cells could cause tumors. A small number of cases now offer strong evidence that…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}